AsiDNA - Onxeo

Drug Profile

AsiDNA - Onxeo

Alternative Names: AsiDNA™; Dbait; Dbait32H; DNA bait; DNA repair therapeutic - Onxeo; DSB bait; DT01; DT1

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DNA Therapeutics
  • Developer Onxeo SA
  • Class Antineoplastics; Gene therapies; Small molecules
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Preclinical Cancer; Solid tumours

Most Recent Events

  • 30 Nov 2017 AsiDNA is still in preclinical trials for Solid tumours in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in France (IV, Injection)
  • 02 Oct 2017 Onxeo plans a phase I trial for Breast cancer (Monotherapy) (IV) by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top